United Arab Emirates recorded 1065607 Coronavirus Cases since the epidemic began, according to the World Health Organization (WHO). In addition, United Arab Emirates reported 2349 Coronavirus Deaths. This dataset includes a chart with historical data for the United Arab Emirates Coronavirus Cases.

As of April 2, 2020, the daily increase of coronavirus (COVID-19) cases in the United Arab Emirates (UAE) amounted to 210 cases. As of the same date, there were eight deaths and 96 recoveries recorded in the country.

As of June 1, 2022 the total number of death caused by coronavirus (COVID-19) in the United Arab Emirates was 2305. The total number of coronavirus (COVID-19) cases to date in the country was around 947.59 thousand.

For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

In past 24 hours, UAE, Asia had N/A new cases, N/A deaths and N/A recoveries.

Project Tycho datasets contain case counts for reported disease conditions for countries around the world. The Project Tycho data curation team extracts these case counts from various reputable sources, typically from national or international health authorities, such as the US Centers for Disease Control or the World Health Organization. These original data sources include both open- and restricted-access sources. For restricted-access sources, the Project Tycho team has obtained permission for redistribution from data contributors. All datasets contain case count data that are identical to counts published in the original source and no counts have been modified in any way by the Project Tycho team, except for aggregation of individual case count data into daily counts when that was the best data available for a disease and location. The Project Tycho team has pre-processed datasets by adding new variables, such as standard disease and location identifiers, that improve data interpretability. We also formatted the data into a standard data format. All geographic locations at the country and admin1 level have been represented at the same geographic level as in the data source, provided an ISO code or codes could be identified, unless the data source specifies that the location is listed at an inaccurate geographical level. For more information about decisions made by the curation team, recommended data processing steps, and the data sources used, please see the README that is included in the dataset download ZIP file.

IntroductionA rapid increase in COVID-19 cases due to the spread of the Delta and Omicron variants in vaccinated populations has raised concerns about the hospitalization risk associated with, and the effectiveness of, COVID-19 vaccines.MethodThis case–control study aims to determine the hospitalization risk associated with the inactivated BBIBP-CorV (Sinopharm) and mRNA BNT162b2 (Pfizer–BionTech) vaccines, and their effectiveness reducing the rate of hospital admission between 28 May 2021 and 13 January 2022, during the Delta and Omicron outbreaks. The estimation of vaccine effectiveness of 4,618 samples was based on the number of patients hospitalized at different vaccination statuses, adjusted for confounding variables.ResultsHospitalization risk increases in patients affected with the Omicron variant if patients are aged ≤ 18 years (OR 6.41, 95% CI 2.90 to 14.17; p < 0.001), and in patients affected with the Delta variant if they are aged > 45 years (OR 3.41, 95% CI 2.21 to 5.50; p < 0.001). Vaccine effectiveness reducing the rate of hospital admission for fully vaccinated participants infected with the Delta and Omicron variants was similar for both the BBIBP-CorV (94%, 95% CI 90% to 97%; 90%, 95% CI 74% to 96%) and BNT162b2 vaccines (95%, 95% CI 61% to 99.3%; 94%, 95% CI 53% to 99%), respectively.DiscussionThe BBIBP-CorV and BNT162b2 vaccines utilized in the UAE vaccination program were highly effective in reducing the rate of COVID-19-related hospitalization during the Delta and Omicron outbreaks, and further effort must be taken to achieve high vaccine coverage rates in children and adolescents in the global context to reduce the hospitalization risk associated with COVID-19 on an international scale.

Factors associated with the symptomatic state of the reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed coronavirus disease 2019 (COVID-19) cases compared with asymptomatic cases.

Crude and adjusted association between symptomatic state and testing positive to coronavirus disease 2019 (COVID-19) in three subsequent reverse transcriptase polymerase chain reaction (RT-PCR) testing rounds.

Records of reported Counts of COVID-19 case counts in United Arab Emirates from 2019-2021. Download is a zipped CSV file with readme.

Correlation between COVID-19 new cases and climate parameters within four timeframes by GCC country.

Background and objectivesThe World Health Organization (WHO) declared the coronavirus disease-19 (COVID-19) pandemic on March 11, 2020. The health care system faced tremendous challenges in providing ethical and high-quality care. The impact of COVID-19 on urological practices varied widely worldwide, including in Arab countries. This study aimed to compare the influence of the COVID-19 pandemic on urology practice in Egypt, the KSA, and the UAE during the first year of the pandemic.MethodsThis sub-analysis assessed the demographics and COVID-19’s effects on urological practice in terms of adjustments to hospital policy, including outpatient consultations, the management of elective and urgent surgical cases, and the continuation of education across the three countries. The availability of personal protective equipment (PPE) and urologists’ emotional, physical, and verbal intimidation during COVID-19 were also compared.ResultsRegarding the impact on hospital policy, consultations replaced by telemedicine were significantly higher in the KSA (36.15%), followed by the UAE (33.3%), then Egypt (10.4%) (P = 0.008). Elective cases requiring ICU admission were 65.1% in Egypt, 45.2% in the KSA, and 58.2% in the UAE and were performed only in high-risk patients. PPE was freely available in 20.8% of the Egyptian hospitals compared to 83.3% in the KSA and 81.8% in the UAE. Online courses were significantly higher in Egypt (70.8%), followed by the UAE (53%) and the KSA (41.7%) (P = 0.02). Emotional intimidation was higher than verbal intimidation, representing 80%, 75.9%, and 76% in the UAE, KSA, and Egypt, respectively.ConclusionThis sub-analysis outlined significant hospital policy changes across the three Arab countries. Exposure to emotional, verbal, and physical intimidation was observed. The development of teleconsultations and online platforms for educational purposes was observed.

In June 2021, the COVID-19 stringency score in the Gulf Cooperation Council (GCC) countries were similar, at about 53.7 in Saudi Arabia, Qatar, the United Arab Emirates, and Oman. The first recorded COVID-19 case in the UAE was in January 29, 2020.

Daily cases and deaths of COVID-19 and climate parameters in GCC countries as of 30th March 2021.

Novel Coronavirus-19 (COVID-19) variants continue to spread worldwide with the development of highly transmissible strains. Several guidelines addressing management of cancer patients during the COVID-19 pandemic have been published, primarily based upon expert opinion. The COVID-19 pandemic has affected all aspects of breast cancer care including screening, diagnosis, treatment and long-term follow-up. Recent reports indicate that m-RNA COVID-19 vaccines can provoke lymphadenopathy in both cancer patients and healthy individuals. Unilateral Axillary Lymphadenopathy (UAL) post-COVID-19 vaccination is a challenging presentation for cancer patients because of the potential for misinterpretation as malignancy. The World Health Organization’s target to vaccinate 70% of the world’s population by mid-2023 is likely to increase the incidence of post COVID-19 vaccination UAL. In this article, we review the published evidence regarding UAL post COVID-19 vaccination and present diverse cases of breast cancer patients where false positive UAL post-COVID-19 vaccination proved to be a therapeutic challenge. The United Arab Emirates (UAE) vaccination program is well ahead of other countries in the world having accomplished the target of 100% vaccination of the population with at least one dose. Therefore, an increasing number of recently vaccinated patients are likely to present with UAL, detected by surveillance imaging, post-vaccination. We have therefore made recommendations regarding the management of cancer patients with UAL post-COVID-19 vaccination in order to avoid misdiagnosis and unnecessary imaging or invasive biopsy procedures.